Form 4: Cabaletta Bio's Chief Medical Officer, David J. Chang, Reports Stock Option Grant

David J. Chang, Chief Medical Officer of Cabaletta Bio, Inc., reports the acquisition of stock options.

Summary

• On March 1, 2024, David J. Chang, the Chief Medical Officer of Cabaletta Bio, Inc., was granted stock options to purchase 130,000 shares of common stock at an exercise price of $23.97 per share.
• The options vest 25% on March 1, 2025, and the remainder vest in twelve substantially equal quarterly installments thereafter, contingent upon continued service.
• Following the transaction, Chang directly owns 130,000 derivative securities.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing indicating standard executive compensation practices. It's neutral to slightly positive as it reflects ongoing investment in key personnel.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Cabaletta Bio.
• Comparable companies such as CRISPR Therapeutics, Beam Therapeutics, and Editas Medicine also utilize stock options to incentivize their leadership teams.
• The vesting schedule of 25% after one year followed by quarterly installments is a typical vesting structure in the industry.

Stakeholder Impact

• The stock option grant aligns the interests of the Chief Medical Officer with those of the shareholders, incentivizing him to contribute to the company's success.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates